Holen Sie sich die Stockscreener-App
16.89
5.69%
0.91
Vorhandelsmarkt:
16.81
-0.08
-0.47%
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Is Arcutis Biotherapeutics Inc. a defensive stockEarnings Overview Summary & Real-Time Stock Entry Alerts - thegnnews.com
Why is Arcutis Biotherapeutics Inc. stock going upQuarterly Growth Report & Weekly Momentum Picks - thegnnews.com
Arcutis Biotherapeutics Inc. Stages Intraday Comeback — Trend Change2025 Market WrapUp & Capital Efficient Trading Techniques - sundaytimes.kr
Applying big data sentiment scoring on Arcutis Biotherapeutics Inc.2025 Price Targets & AI Enhanced Trading Signals - Newser
What recovery options are there for Arcutis Biotherapeutics Inc.2025 Market Outlook & AI Forecasted Entry/Exit Points - Newser
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know - MSN
Combining machine learning predictions for Arcutis Biotherapeutics Inc.Quarterly Earnings Report & Entry and Exit Point Strategies - Newser
Is Arcutis Biotherapeutics Inc. still worth holding after the dipQuarterly Investment Review & Precise Buy Zone Identification - Newser
ARQT’s Stock Journey: What Investors Need to Know About Arcutis Biotherapeutics Inc’s Performance - investchronicle.com
Smart tools for monitoring Arcutis Biotherapeutics Inc.’s price actionTrade Entry Summary & Fast Gain Stock Trading Tips - Newser
How Arcutis Biotherapeutics Inc. stock performs during market volatilityTrade Exit Report & Free AI Powered Buy and Sell Recommendations - Newser
Arcutis Biotherapeutics Inc. stock chart pattern explainedBond Market & Verified Momentum Stock Watchlist - Newser
Analyzing net buyer seller activity in Arcutis Biotherapeutics Inc.Recession Risk & Verified High Yield Trade Plans - Newser
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
Why Arcutis Biotherapeutics Inc. stock attracts strong analyst attentionBear Alert & Momentum Based Trading Ideas - Newser
Arcutis Biotherapeutics Inc. Recovers — But Is It SustainableWeekly Hot Picks With Buy Confidence Released - sundaytimes.kr
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Arcutis Biotherapeutics' Burnett Patrick Sells 3847 Shares at $14.03 per Share - AInvest
Burnett, Arcutis Biotherapeutics EVP, sells $53,988 in ARQT stock By Investing.com - Investing.com Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $22.00 - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Rating Increased to Buy at Wall Street Zen - Defense World
Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 - MSN
Arcutis Biotherapeutics Awards Restricted Stock Units to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Weigh In on GoodRx Holdings (GDRX) and Arcutis Biotherapeutics (ARQT) - AInvest
Arcutis Biotherapeutics Receives Buy Rating and $21.00 Price Target from Morgan Stanley - AInvest
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates - MSN
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $21 to $25 - 富途牛牛
Seborrhoeic Dermatitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma - Barchart.com
Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts - Investing.com
Arcutis' Path to Profitability and Market Leadership in Dermatology - AInvest
Arcutis Biotherapeutics: Scaling ZORYVE Foam to Redefine Psoriasis Treatment and Drive Sustainable Growth - AInvest
Transcript : Arcutis Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth - TipRanks
Arcutis (ARQT) Q2 Revenue Soars 164% - The Globe and Mail
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating - TipRanks
Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics - Barchart.com
Molluscum Contagiosum Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Asana BioSciences - Barchart.com
Arcutis Q2 2025 slides: Revenue soars 164% YoY as portfolio expansion drives growth - Investing.com Australia
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q2 Revenue $81.5M, vs. FactSet Est of $73.7M - MarketScreener
Arcutis Reports Massive 164% Revenue Jump, Hits 1M Prescriptions and Wins FDA Approval - Stock Titan
Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics - Menafn
Arcutis Biotherapeutics director Welgus sells $142,982 in shares - Investing.com India
Top Executives Sell Significant Shares of Arcutis Biotherapeutics! - TipRanks
Arcutis Biotherapeutics director Welgus sells $142,982 in shares By Investing.com - Investing.com Nigeria
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 By Investing.com - Investing.com Australia
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 - Investing.com India
Arcutis Biotherapeutics director Watanabe sells $165k in shares By Investing.com - Investing.com Canada
Hand Eczema Clinical Trials, Companies, Therapeutic - openPR.com
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Seborrhoeic Dermatitis Clinical Trials, Companies, - openPR.com
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):